A chemo/chemodynamic nanoparticle based on hyaluronic acid induces ferroptosis and apoptosis for triple-negative breast cancer therapy

被引:18
|
作者
Wang, Ning [1 ]
Zhang, Qiyu [1 ]
Wang, Zhuoya [1 ]
Liu, Yichao [1 ]
Yang, Sen [1 ]
Zhao, Xuerong [1 ]
Peng, Jinyong [1 ,2 ,3 ]
机构
[1] Dalian Med Univ, Coll Pharm, Dalian 116044, Peoples R China
[2] Anhui Univ Chinese Med, Coll Pharm, Hefei 230012, Peoples R China
[3] Hubei Univ Chinese Med, Coll Pharm, Wuhan 430065, Peoples R China
关键词
Chemo/chemodynamic therapy; Ferroptosis/apoptosis; Hyaluronic acid; Controlled drugs release; TNBC; DRUG-DELIVERY SYSTEM;
D O I
10.1016/j.carbpol.2024.121795
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Triple-negative breast cancer (TNBC) poses a serious threat to women's life and health due to its high malignancy, strong invasiveness, and propensity for early recurrence and metastasis. Therefore, there is an urgent need to develop a highly effective and low-toxic TNBC treatment scheme to enhance the anti-cancer efficacy and prolong the survival of patients. In this work, we designed and synthesized a chemodynamic therapy (CDT) agent (HA-Fc-Mal). The chemo/chemodynamic (CT/CDT) nanoparticle (HCM@DOX) based on hyaluronic acid induces ferroptosis and apoptotic for TNBC therapy was constructed via self-assembled of HA-Fc-Mal and doxorubicin (DOX). HCM@DOX orderly realized the TNBC targeting, controlled DOX release, GSH depletion and induce ROS erupt. In vivo and in vitro experiments confirmed that HCM@DOX inhibited the growth of 4 T1 tumors through ferroptosis and apoptosis, and the tumor inhibition rate was as high as 81.87 %. In addition, HCM@DOX significantly inhibited lung metastasis and exhibited excellent biosafety. Overall, our findings offer a new strategy for TNBC therapy using a CT/CDT nanoparticle that induces ferroptosis and apoptosis.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Inhibition of fatty-acid oxidation as a therapy for triple-negative breast cancer
    Goga, A.
    Camarda, R.
    Zhou, A. Y.
    Kohnz, R. A.
    Balakrishnan, S.
    Anderton, B.
    Mahieu, C.
    Eyob, H.
    Krings, G.
    Nomura, D. K.
    CANCER RESEARCH, 2016, 76
  • [33] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    ONCOLOGIST, 2011, 16 : 71 - 78
  • [34] Progress in systemic therapy for triple-negative breast cancer
    Hongnan Mo
    Binghe Xu
    Frontiers of Medicine, 2021, 15 (01) : 1 - 10
  • [35] Triple-negative breast cancer and the potential for targeted therapy
    Jhan, Jing-Ru
    Andrechek, Eran R.
    PHARMACOGENOMICS, 2017, 18 (17) : 1595 - 1609
  • [36] Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
    Abramson, Vandana G.
    Lehmann, Brian D.
    Ballinger, Tarah J.
    Pietenpol, Jennifer A.
    CANCER, 2015, 121 (01) : 8 - 16
  • [37] Progress in systemic therapy for triple-negative breast cancer
    Mo, Hongnan
    Xu, Binghe
    FRONTIERS OF MEDICINE, 2021, 15 (01) : 1 - 10
  • [38] Ferroptosis as a promising targeted therapy for triple negative breast cancer
    Mokhtarpour, Kasra
    Razi, Sepideh
    Rezaei, Nima
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (03) : 497 - 513
  • [39] Directed Therapy of Subtypes of Triple-Negative Breast Cancer
    Carey, Lisa A.
    ONCOLOGIST, 2010, 15 : 49 - 56
  • [40] New Vaccine Therapy for Triple-Negative Breast Cancer
    Harris, Paul E.
    Rubsamen, Reid
    CURRENT BREAST CANCER REPORTS, 2024, 16 (03) : 288 - 301